The aim of this study is to compare the success rate of outpatient surgery after holmium LASER enucleation of the prostate (HoLEP) for the treatment of BPH with and without the use of the MOSES 2.0 effect.

HoLEP is in the process of becoming the new reference surgical treatment for BPH with the main advantages over monopolar transurethral resection (TURPm) and high approach adenomectomy (AVH): the significant reduction in morbidity perioperative period and therefore the reduction in the length of hospital stay. This reduction in length of stay has led to the development of outpatient care with encouraging results. The main cause of discharge failure on D0 is the persistence of postoperative hematuria requiring maintenance of bladder irrigation. MOSESTM 2.0 technology has the advantage of better hemostasis compared to the LASER LP100 currently used. The objective of this study is to evaluate the influence of MOSESTM 2.0 technology on the outpatient success rate in patients operated on for HoLEP for BPH.

Inclusion Criteria:

• Subject over 50 years old
• BPH whose symptoms require surgical management
• Preoperative prostate volume measured by ultrasound (suprapubic or transrectal) ≥ 40g
• IPSS score > 15 and Quality of Life score ≥ 3
• Maximum urinary output (Qmax) < 15 ml/sec

Exclusion Criteria:

• Inability to read or write French
• Patients with comorbidities contraindicating general anesthesia
• Patients not eligible for outpatient care according to French recommendations (high risk of complications after general anesthesia, place of residence more than 150 km from an emergency department, alone at home the night following the intervention) .
• History of BPH surgery
• History of prostate cancer
• Preoperative prostate volume measured by ultrasound (suprapubic or transrectal) < 40g
• Existence or history of urethral stricture
• Existence or suspicion of a "neurological" bladder
• Positive preoperative cytobacteriological examination not treated appropriately
• Adult patients subject to a legal protection measure or unable to express their consent
• Patients deprived of liberty by a judicial or administrative decision or hospitalized without consent or admitted to a health or social establishment for purposes other than research

• Patients who require HoLEP for Begnign Prostate Hypertrophy eligible for outpatient management
• Patients having been managed by HoLEP (without MOSES 2.0) in ambulatory care since January 2016 in the urology department of the Bordeaux University Hospital.